Frustrated at ongoing lack of access in low- or middle-income countries to Vertex’s Trikafta/Kaftrio (elexacaftor/ivacaftor/tezacaftor) landmark treatment for cystic fibrosis, and with Vertex “making no effort to address this gross health inequality resulting from their business practice,” a coalition of activists and patients in four countries have commenced action to override the originator’s patents, including a bid for a compulsory license to the originator’s IP.
Three of the countries represented, Brazil, India and South Africa, form part of the five-strong BRICS, the leading emerging economic...
